Organization | Intergroupe Francophone du Myelome

Intergroupe Francophone du Myelome Report issue

Academic/Hospital Phase 2 Phase 3

Founded: Paris France (1994)

Organization Overview

First Clinical Trial

2006

NCT00430365

First Marketed Drug

None

First NDA Approval

None

Last Known Activity

2021

Timeline

NOW

Now

Alternative names

Intergroupe Francophone du Myelome

Active Ingredients

Drugs in Phase 3 Trials (7)

bortezomib (velcade) (5 trials)

daratumumab (darzalex) (2 trials)

dexamethasone (2 trials)

Isatuximab (Sarclisa) (3 trials)

lenalidomide (revlimid) (3 trials)

thalidomide (Thalomid) (3 trials)

urea (5 trials)

Drugs in Phase 2 Trials (4)

autologous mononuclear stem cell (1 trial)

bendamustine (treanda) (1 trial)

ixazomib (ninlaro) (1 trial)

pomalidomide (pomalyst) (1 trial)

Drugs in Other Trials (2)

melphalan (alkeran) (1 trial)

prednisone (meticorten) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)

Multiple Myeloma (Phase 3)

Neoplasms, Plasma Cell (Phase 3)

Recurrence (Phase 2)

Overview

Highest Phase: Phase 3
# of Trials: 12
# of Trial APIs: 13